{"id":765672,"date":"2023-06-23T07:03:21","date_gmt":"2023-06-23T11:03:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/"},"modified":"2023-06-23T07:03:21","modified_gmt":"2023-06-23T11:03:21","slug":"aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/","title":{"rendered":"Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes<\/b><\/p>\n<p>LEXINGTON, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\n(Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that it will be added to the Russell 2000\u00ae and the Russell 3000\u00ae indexes, effective after the U.S. equity markets close on June 23, 2023.\n<\/p>\n<p>\nAnnual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 28 2023, ranking them by total market capitalization, including both the Russell 3000\u00ae and Russell Microcap\u00ae Indexes. Membership in the US all-cap Russell 3000\u00ae Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.\n<\/p>\n<p>\nRussell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12.1 trillion in assets are benchmarked to or invested in products based on the Russell U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider.\n<\/p>\n<p><b>About Aldeyra<\/b><\/p>\n<p>\nAldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX\u2011629, ADX\u2011246, ADX\u2011248, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease (under U.S. Food and Drug Administration New Drug Application Review) and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of proliferative vitreoretinopathy and retinitis pigmentosa.\n<\/p>\n<p><b>Safe Harbor Statement<\/b><\/p>\n<p>\nThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cobjective,\u201d \u201cintend,\u201d \u201cshould,\u201d &#8220;could,&#8221; \u201ccan,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201canticipate,\u201d \u201cproject,\u201d \u201con track,\u201d \u201con schedule,\u201d \u201ctarget,\u201d \u201cdesign,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201caim,\u201d \u201cplan,\u201d or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Important factors that may cause actual results to differ material from those reflected in Aldeyra\u2019s forward-looking statements, include, among others, the factors that are described in the \u201cRisk Factors\u201d and \u201cManagement&#8217;s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of Aldeyra&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, and Aldeyra\u2019s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC&#8217;s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2F&amp;esheet=53429086&amp;newsitemid=20230623965905&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.sec.gov%2F&amp;index=1&amp;md5=0b029128ca26229bb05e533684ebfaf1\">https:\/\/www.sec.gov\/<\/a>. Additional factors may be described in those sections of Aldeyra&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, expected to be filed with the SEC in the third quarter of 2023.\n<\/p>\n<p>\nIn addition to the risks described above and in Aldeyra&#8217;s other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra&#8217;s results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230623965905r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230623965905\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230623965905\/en\/<\/a><\/span><\/p>\n<p><b><i>Investor &amp; Media:<br \/>\n<\/i><\/b><br \/>David Burke<br \/>\n<br \/>Tel: (917) 618-2651<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investorrelations@aldeyra.com\">investorrelations@aldeyra.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Infectious Diseases FDA Clinical Trials Biotechnology Health Pharmaceutical Other Science Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that it will be added to the Russell 2000\u00ae and the Russell 3000\u00ae indexes, effective after the U.S. equity markets close on June 23, 2023. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 28 2023, ranking them by total market capitalization, including both the Russell 3000\u00ae and Russell Microcap\u00ae Indexes. Membership in the US all-cap Russell 3000\u00ae Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index as well &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-765672","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that it will be added to the Russell 2000\u00ae and the Russell 3000\u00ae indexes, effective after the U.S. equity markets close on June 23, 2023. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 28 2023, ranking them by total market capitalization, including both the Russell 3000\u00ae and Russell Microcap\u00ae Indexes. Membership in the US all-cap Russell 3000\u00ae Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index as well &hellip; Continue reading &quot;Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-23T11:03:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230623965905r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes\",\"datePublished\":\"2023-06-23T11:03:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\\\/\"},\"wordCount\":692,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230623965905r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\\\/\",\"name\":\"Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230623965905r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-06-23T11:03:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230623965905r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230623965905r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/","og_locale":"en_US","og_type":"article","og_title":"Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","og_description":"Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that it will be added to the Russell 2000\u00ae and the Russell 3000\u00ae indexes, effective after the U.S. equity markets close on June 23, 2023. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 28 2023, ranking them by total market capitalization, including both the Russell 3000\u00ae and Russell Microcap\u00ae Indexes. Membership in the US all-cap Russell 3000\u00ae Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index as well &hellip; Continue reading \"Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-23T11:03:21+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230623965905r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes","datePublished":"2023-06-23T11:03:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/"},"wordCount":692,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230623965905r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/","name":"Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230623965905r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-06-23T11:03:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230623965905r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230623965905r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldeyra-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aldeyra Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=765672"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765672\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=765672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=765672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=765672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}